VERU

VERU

USD

Veru Inc. Common Stock

$2.650+0.070 (2.713%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$2.580

Haut

$2.650

Bas

$2.580

Volume

0.18M

Fondamentaux de l'Entreprise

Capitalisation Boursière

42.5M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.18M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $2.42Actuel $2.650Haut $14.2

Rapport d'Analyse IA

Dernière mise à jour: 10 nov. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges

Market Snapshot

Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns


Recent Performance: Turbulent Descent

Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:

  • Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
  • Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
  • Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.

Technical Signals: Mixed Messages

  • Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
  • Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
  • MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.

Fundamentals: Value Trap or Hidden Potential?

  • Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
  • **High-Risk

Actualités Connexes

GlobeNewswire

Veru to Present Two Abstracts at ObesityWeek 2025

MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Voir plus
Veru to Present Two Abstracts at ObesityWeek 2025
GlobeNewswire

Veru Announces Pricing of $25 Million Public Offering

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Voir plus
Veru Announces Pricing of $25 Million Public Offering

Prédiction IABeta

Recommandation IA

Haussier

Mis à jour le: 10 nov. 2025, 14:42

BaissierNeutreHaussier

58.4% Confiance

Risque et Trading

Niveau de Risque3/5
Risque Moyen
Adapté Pour
Valeur
Guide de Trading

Point d'Entrée

$2.52

Prise de Bénéfices

$2.61

Stop Loss

$2.30

Facteurs Clés

Le PDI 15.4 est au-dessus du MDI 14.1 avec un ADX de 19.0, suggérant une tendance haussière
Le volume de transactions est 1.9x la moyenne (3,174), indiquant une participation accrue au marché
Le MACD 0.0119 est en dessous de la ligne de signal 0.0162, indiquant un croisement baissier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.